Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest
NAN LI, DONGHAI ZHENG, JIE XUE, WEIXING GUO, JIE SHI, JUXIAN SUN, CHONGDE LU, WEIDA ZHENG, MENGCHAO WU and SHUQUN CHENG
Exp Ther Med 9: 1709-1718, 2015; DOI: 10.3892/etm.2015.2351
After the publication of the article, the authors noted that they had made an error in the titles and legends of Figs. 1 and 2. OS (Overall Survival) in the title and legend of Fig. 1 should be changed to DFS and Disease-Free Survival. DFS in the title and legend of Fig. 2 should be changed to OS and overall survival. The authors provide the correct figures and legends below.
Comparison of the postoperative DFS rates of patients with HCC treated with liver-protection drugs only (control group) or with liver-protection drugs and cidan (treatment group). HCC, hepatocellular carcinoma; DFS, Disease-free survival.
Comparison of the postoperative OS times of patients with HCC treated with liver-protection drugs only (control group) or with liver-protection drugs and cidan (treatment group). HCC, hepatocellular carcinoma; OS, overall survival.